Granules eyes first to file status, 180 days exclusivity on generic cancer drug Ruxolitinib in U.S.

The Paragraph IV certification sought is with respect to applicable patents listed in the U.S. FDA’s Orange Book. Granules said it has also issued the requisite notice to the relevant parties in accordance with U.S. regulatory requirements.
Read the full story on The Hindu Opens thehindu.com in a new tab
Advertisement
CallZenixAI Voice Bot, Dialer & IVR SolutionsCloud dialer and contact-center software for your teamKnow more
This is a short summary of a story published by The Hindu, shown with a link to the original. The full story, photo and reporting belong to The Hindu.











